P067 A novel validated patient decision aid to enhance shared decision making for the management of actinic keratosis

Geoffrey Brent,Caroline Beardmore,Kate Mayers,Alberto Barea,Venura Samarasinghe,Vanessa Pinder,Julia Soo,Victoria Akhras,Zainab Jiyad

DOI: https://doi.org/10.1093/bjd/ljae090.094

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract Actinic keratoses (AKs) are common premalignant lesions relating to chronic ultraviolet exposure. Several management options exist, including active surveillance, multiple topical therapies, cryotherapy, curettage and cautery, and photodynamic therapy, each with their own risks, benefits and efficacy. Best practice currently involves shared decision making between patient and clinician, particularly when there are numerous management options. Patient decision aids (PDAs) can be beneficial in the shared decision-making process. Between December 2022 and August 2023 we developed and validated a PDA for the management of AKs, in concordance with the International Patient Decision Aids Standards. A two-page leaflet was created with key information on the standard management options, such as what the treatment involves, side-effects and efficacy. Alpha testing of the draft PDA was conducted initially, with positive feedback from clinicians and patients. Beta testing was then undertaken, in which the PDA was used in consultations with 21 consecutive patients across three separate hospital trusts in dermatology clinics. Included patients were over 18 years of age and diagnosed clinically or histologically with one or more AKs. Patients were excluded if there was any suspicion of squamous cell carcinoma, or if they had tender or hypertrophic AKs. Two validated outcome measures, the Decisional Conflict Scale (DCS) and the nine-item Shared Decision Making Questionnaire (SDM-Q-9), were used for all patients. The majority of patients (75%) indicated a high level of decisional conflict prior to using the PDA, with a total mean DCS score of 53.0 (95% confidence interval 43.2–62.8), where a higher value corresponds with increasing decisional conflict. Following use of the PDA, the total mean DCS score improved to 13.0 (95% confidence interval 8.0–17.9). This represents a significant reduction in DCS score (P < 0.001), with the majority of responses as ‘strongly agree’ and ‘agree’ that the PDA facilitated their management decision. The total SDM-Q-9 score was 791/900 (87.9%), which indicates a high level of shared decision making following use of the PDA. As AKs can be managed in numerous ways, information given to patients can be overwhelming, making the decision more challenging for patients. A PDA given to the patient can reduce decisional conflict and improve the shared decision-making process. We suggest that this validated PDA can be used in various settings to facilitate informed care: during primary care consultations, in secondary care in both specialist nurse and doctor-led clinics, and also at the interface between primary and secondary care when responding to Advice and Guidance queries.

dermatology